Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

Nanchang University

Status: Unknown

Conditions: Proteinuria; HBVe-antigen

Study type: Observational

Funder types: Other

Identifiers

NCT01152060

NCT00100504

Details and patient eligibility

About

Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Full description

lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative

Exclusion criteria

• Primary MN patients, HBV-DNA positive

Trial design

10 participants in 2 patient groups

prednisone

prednisone and anti-virus